203 filings
8-K
EVFM
Evofem Biosciences, Inc.
15 May 24
Evofem Biosciences Announces Financial Results for the First Quarter of 2024
6:50am
8-K
EVFM
Evofem Biosciences, Inc.
2 May 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EVFM
Evofem Biosciences, Inc.
28 Mar 24
Regulation FD Disclosure
5:11pm
8-K
EVFM
Evofem Biosciences, Inc.
27 Mar 24
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
8:36am
8-K
EVFM
Evofem Biosciences, Inc.
6 Mar 24
Entry into a Material Definitive Agreement
5:14pm
8-K
adlqzhqcl0dmx 8i
1 Feb 24
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
9:05am
8-K
vox4m9o3zbmyb pvvo8g
31 Jan 24
Entry into a Material Definitive Agreement
4:26pm
8-K/A
w2xb5qi 53
25 Jan 24
Financial Statements and Exhibits
4:23pm
8-K
vm5lm hdhvqwg3jq9p
11 Jan 24
Entry into a Material Definitive Agreement
4:53pm
8-K
kpmf9as 18gtu9f50
26 Dec 23
Entry into a Material Definitive Agreement
5:37pm
8-K
4lgh4rc
12 Dec 23
Entry into a Material Definitive Agreement
5:17pm
8-K
vshoqa
7 Dec 23
Entry into a Material Definitive Agreement
4:05pm
8-K
rgjdfinhrofm
14 Nov 23
Evofem Biosciences Announces Financial Results for the Third Quarter of 2023
12:00am
8-K
dx9ao
24 Oct 23
Evofem Biosciences Announces Preliminary Results for the Third Quarter of 2023
7:40am
8-K
vz5 xh9p1ga
3 Oct 23
Entry into a Material Definitive Agreement
4:07pm
8-K
buj6gd8f bksp
27 Sep 23
Evofem Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi Until Evofem’s Phexxi Patents Expire
8:50am
8-K
uns1dmrgiq3img
15 Sep 23
Amendments to Articles of Incorporation or Bylaws
4:49pm
8-K
o1bo29
11 Sep 23
Entry into a Material Definitive Agreement
8:01am
8-K
j30b1 rn52x
28 Aug 23
Regulation FD Disclosure
4:30pm
8-K/A
q05gz 23b8hx
18 Aug 23
Entry into a Material Definitive Agreement
4:05pm